Brief: First Wave Biopharma Provides Update On Ind Filing For Phase 2 Trial Of Enhanced Microgranule Formulation Of Adrulipase For Exocrine Pancreatic Insufficiency

GridAI Technologies

13/01/2023 22:59

Jan 13 (Reuters) - First Wave BioPharma Inc  FWBI.O :
    * FIRST WAVE BIOPHARMA PROVIDES UPDATE ON IND FILING FOR
PHASE 2
TRIAL OF ENHANCED MICROGRANULE FORMULATION OF ADRULIPASE FOR
EXOCRINE PANCREATIC INSUFFICIENCY
    * FIRST WAVE BIOPHARMA PROVIDES UPDATE ON IND FILING FOR
PHASE 2
TRIAL OF ENHANCED MICROGRANULE FORMULATION OF ADRULIPASE FOR
EXOCRINE PANCREATIC INSUFFICIENCY
    * FIRST WAVE BIOPHARMA INC - FIRST WAVE BIOPHARMA HAS BEEN
IN
CONVERSATIONS WITH FDA AND EXPECTS A FORTHCOMING RESPONSE AROUND
END OF JANUARY
    * FIRST WAVE BIOPHARMA - UNDER FDA'S POLICY GUIDELINES, FDA
STRIVES TO COMPLETE ITS REVIEW OF PHASE 2 PROTOCOLS WITHIN 60
DAYS, BUT MAY TAKE LONGER

Source text for Eikon:  ID:nGNX4s8pSr 
Further company coverage:  FWBI.O 
 ((reuters.briefs@thomsonreuters.com;))